Serum immunoglobulin fused interferon-alpha inhibited tumor growth in athymic mice bearing colon 26 adenocarcinoma cells.
- Author:
Jun Sung KIM
1
;
Kyeong Nam YU
;
Mi Suk NOH
;
Min Ah WOO
;
Sung Jin PARK
;
Jin Hong PARK
;
Jin HUA
;
Hyun Sun CHO
;
Soon Kyung HWANG
;
Eun Sun LEE
;
Youn Sun CHUNG
;
In Young CHOI
;
Se Chang KWON
;
Myung Haing CHO
Author Information
- Publication Type:Original Article
- Keywords: adenocarcinoma cell; interferon; serum immunoglobulin; tumor growth inhibition
- MeSH: Adenocarcinoma/*drug therapy; Alanine Transaminase/blood; Animals; Antineoplastic Agents/chemistry/pharmacology; Blood Urea Nitrogen; Dose-Response Relationship, Drug; Immunoglobulins/*chemistry/*pharmacology; Interferon Alfa-2a/chemistry/pharmacology; Interferon-alpha/*chemistry/*pharmacology; Mice; Mice, Nude; Neoplasms, Experimental/*drug therapy; Polyethylene Glycols/chemistry/pharmacology; Recombinant Fusion Proteins/chemistry/pharmacology
- From:Journal of Veterinary Science 2008;9(1):45-50
- CountryRepublic of Korea
- Language:English
- Abstract: Interferon (IFN) has therapeutic potential for a wide range of infectious and proliferative disorders. However, the half-life of IFN is too short to have a stable therapeutic effect. To overcome this problem, serum immunoglobulin has been fused to IFN. In this study, the efficacy of serum immunoglobulin fused INFs (si-IFN1 and si-IFN2) was evaluated on athymic mice bearing colon 26 adenocarcinoma cells. Seven days after the implantation of tumor cells, each group of mice was injected once a week with si-IFN1 and si-IFN2 at two different concentrations (10 x : 30 microgram/kg and 50 x : 150 microgram/kg). A slight anti-tumoral effect was observed in all 10 x groups compared to the control. In the 50 x groups, however, si-IFN1 and si-IFN2 showed significant anti- tumoral effects compared to the control. To gain more information on the mechanisms associated with the decrease of tumor size, a Western blot assay of apoptosis-related molecules was performed. The protein expression of cytochrome c, caspase 9, 6, and 3 were increased by si-IFN1 and si-IFN2. These 2 IFNs also increased the expressions of p53, p21, Bax and Bad. Interestingly, si-IFN1 and si-IFN2 decreased the expression of VEGF-beta. Taken together, serum immunoglobulin fused IFNs increased therapeutic efficacy under current experimental condition.
